Research ExplorerPublicationsEvaluation of Sustained Minimal Residual Disease Negativity ...

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Standard

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. / Avet-Loiseau, Hervé; San-Miguel, Jesus; Casneuf, Tineke; Iida, Shinsuke; Lonial, Sagar; Usmani, Saad Z; Spencer, Andrew; Moreau, Philippe; Plesner, Torben; Weisel, Katja; Ukropec, Jon; Chiu, Christopher; Trivedi, Sonali; Amin, Himal; Krevvata, Maria; Ramaswami, Priya; Qin, Xiang; Qi, Mia; Sun, Steven; Qi, Ming; Kobos, Rachel; Bahlis, Nizar J.

In: J CLIN ONCOL, Vol. 39, No. 10, 01.04.2021, p. 1139-1149.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Avet-Loiseau, H, San-Miguel, J, Casneuf, T, Iida, S, Lonial, S, Usmani, SZ, Spencer, A, Moreau, P, Plesner, T, Weisel, K, Ukropec, J, Chiu, C, Trivedi, S, Amin, H, Krevvata, M, Ramaswami, P, Qin, X, Qi, M, Sun, S, Qi, M, Kobos, R & Bahlis, NJ 2021, 'Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR', J CLIN ONCOL, vol. 39, no. 10, pp. 1139-1149. https://doi.org/10.1200/JCO.20.01814

APA

Avet-Loiseau, H., San-Miguel, J., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A., Moreau, P., Plesner, T., Weisel, K., Ukropec, J., Chiu, C., Trivedi, S., Amin, H., Krevvata, M., Ramaswami, P., Qin, X., Qi, M., Sun, S., ... Bahlis, N. J. (2021). Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J CLIN ONCOL, 39(10), 1139-1149. https://doi.org/10.1200/JCO.20.01814

Vancouver

Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J CLIN ONCOL. 2021 Apr 1;39(10):1139-1149. https://doi.org/10.1200/JCO.20.01814

Bibtex

@article{db391af3aae64154b64d6c5f8e423052,
title = "Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR",
abstract = "PURPOSE: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies.METHODS: MRD was assessed via next-generation sequencing (10-5) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (≥ 6 or ≥ 12 months) was evaluated in the intention-to-treat (ITT) and ≥ CR populations.RESULTS: The median follow-up was 54.8 months in POLLUX and 50.2 months in CASTOR. In the ITT population, MRD-negativity rates were 32.5% versus 6.7% for D-Rd versus lenalidomide and dexamethasone (Rd) and 15.1% versus 1.6% for D-Vd versus bortezomib and dexamethasone (Vd; both P < .0001). Higher MRD negativity rates were achieved in ≥ CR patients in POLLUX (D-Rd, 57.4%; Rd, 29.2%; P = .0001) and CASTOR (D-Vd, 52.8%; Vd, 17.4%; P = .0035). More patients in the ITT population achieved sustained MRD negativity ≥ 6 months with D-Rd versus Rd (20.3% v 2.1%; P < .0001) and D-Vd versus Vd (10.4% v 1.2%; P < .0001), and ≥ 12 months with D-Rd versus Rd (16.1% v 1.4%; P < .0001) and D-Vd versus Vd (6.8% v 0%). Similar results for sustained MRD negativity were observed among ≥ CR patients. More patients in the daratumumab-containing arms achieved MRD negativity and sustained MRD negativity, which were associated with prolonged progression-free survival.CONCLUSION: Daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes.",
author = "Herv{\'e} Avet-Loiseau and Jesus San-Miguel and Tineke Casneuf and Shinsuke Iida and Sagar Lonial and Usmani, {Saad Z} and Andrew Spencer and Philippe Moreau and Torben Plesner and Katja Weisel and Jon Ukropec and Christopher Chiu and Sonali Trivedi and Himal Amin and Maria Krevvata and Priya Ramaswami and Xiang Qin and Mia Qi and Steven Sun and Ming Qi and Rachel Kobos and Bahlis, {Nizar J}",
year = "2021",
month = apr,
day = "1",
doi = "10.1200/JCO.20.01814",
language = "English",
volume = "39",
pages = "1139--1149",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

RIS

TY - JOUR

T1 - Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

AU - Avet-Loiseau, Hervé

AU - San-Miguel, Jesus

AU - Casneuf, Tineke

AU - Iida, Shinsuke

AU - Lonial, Sagar

AU - Usmani, Saad Z

AU - Spencer, Andrew

AU - Moreau, Philippe

AU - Plesner, Torben

AU - Weisel, Katja

AU - Ukropec, Jon

AU - Chiu, Christopher

AU - Trivedi, Sonali

AU - Amin, Himal

AU - Krevvata, Maria

AU - Ramaswami, Priya

AU - Qin, Xiang

AU - Qi, Mia

AU - Sun, Steven

AU - Qi, Ming

AU - Kobos, Rachel

AU - Bahlis, Nizar J

PY - 2021/4/1

Y1 - 2021/4/1

N2 - PURPOSE: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies.METHODS: MRD was assessed via next-generation sequencing (10-5) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (≥ 6 or ≥ 12 months) was evaluated in the intention-to-treat (ITT) and ≥ CR populations.RESULTS: The median follow-up was 54.8 months in POLLUX and 50.2 months in CASTOR. In the ITT population, MRD-negativity rates were 32.5% versus 6.7% for D-Rd versus lenalidomide and dexamethasone (Rd) and 15.1% versus 1.6% for D-Vd versus bortezomib and dexamethasone (Vd; both P < .0001). Higher MRD negativity rates were achieved in ≥ CR patients in POLLUX (D-Rd, 57.4%; Rd, 29.2%; P = .0001) and CASTOR (D-Vd, 52.8%; Vd, 17.4%; P = .0035). More patients in the ITT population achieved sustained MRD negativity ≥ 6 months with D-Rd versus Rd (20.3% v 2.1%; P < .0001) and D-Vd versus Vd (10.4% v 1.2%; P < .0001), and ≥ 12 months with D-Rd versus Rd (16.1% v 1.4%; P < .0001) and D-Vd versus Vd (6.8% v 0%). Similar results for sustained MRD negativity were observed among ≥ CR patients. More patients in the daratumumab-containing arms achieved MRD negativity and sustained MRD negativity, which were associated with prolonged progression-free survival.CONCLUSION: Daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes.

AB - PURPOSE: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies.METHODS: MRD was assessed via next-generation sequencing (10-5) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (≥ 6 or ≥ 12 months) was evaluated in the intention-to-treat (ITT) and ≥ CR populations.RESULTS: The median follow-up was 54.8 months in POLLUX and 50.2 months in CASTOR. In the ITT population, MRD-negativity rates were 32.5% versus 6.7% for D-Rd versus lenalidomide and dexamethasone (Rd) and 15.1% versus 1.6% for D-Vd versus bortezomib and dexamethasone (Vd; both P < .0001). Higher MRD negativity rates were achieved in ≥ CR patients in POLLUX (D-Rd, 57.4%; Rd, 29.2%; P = .0001) and CASTOR (D-Vd, 52.8%; Vd, 17.4%; P = .0035). More patients in the ITT population achieved sustained MRD negativity ≥ 6 months with D-Rd versus Rd (20.3% v 2.1%; P < .0001) and D-Vd versus Vd (10.4% v 1.2%; P < .0001), and ≥ 12 months with D-Rd versus Rd (16.1% v 1.4%; P < .0001) and D-Vd versus Vd (6.8% v 0%). Similar results for sustained MRD negativity were observed among ≥ CR patients. More patients in the daratumumab-containing arms achieved MRD negativity and sustained MRD negativity, which were associated with prolonged progression-free survival.CONCLUSION: Daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes.

U2 - 10.1200/JCO.20.01814

DO - 10.1200/JCO.20.01814

M3 - SCORING: Journal article

C2 - 33513030

VL - 39

SP - 1139

EP - 1149

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 10

ER -